Conley Chee - 31 Mar 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role: Chief Commercial Officer
Signature: /s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol: SYRS
Transactions as of: 31 Mar 2023
Net transactions value: -$1,698
Form type: 4
Filing time: 04 Apr 2023, 18:56:43 UTC
Previous filing: 21 Feb 2023
Next filing: 02 Nov 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SYRS	Common Stock	Options Exercise		+2,000			2,000	31 Mar 2023	Direct	F1, F2
transaction	SYRS	Common Stock	Tax liability	$1,698	-658	-33%	$2.58	1,342	03 Apr 2023	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SYRS	Restricted Stock Units	Options Exercise	$0	-2,000	-25%	$0.000000	6,000	31 Mar 2023	Common Stock	2,000		Direct	F2, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock received upon vesting of a restricted stock unit award.
F2	On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F3	Represents shares used to cover tax withholding on a restricted stock unit release.
F4	Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F5	Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.